The company ABLE Human Motion, supported by the PASS programme, incorporates 6 exoskeletons for neuromuscular rehabilitation into the Catalan healthcare system
CatSalut is bringing cutting-edge technology into Catalan hospitals with thirteen exoskeletons. Six of these were developed by ABLE Human Motion, a startup accelerated by Biocat through PASS and CRAASH Barcelona.
The Catalan Health Service (CatSalut), under the framework of the Comprehensive health system for public use in Catalonia (SISCAT), has acquired thirteen robotic exoskeletons for rehabilitation of patients with neuromuscular diseases. Six of these devices were developed by ABLE Human Motion, a BioRegion of Catalonia startup specializing in healthcare innovation, which has received key support from Biocat through programs like the Healthcare System Access Program (PASS) and CRAASH Barcelona.
Innovation and business acceleration in healthcare
ABLE Human Motion has been supported by Biocat with strategic, legal and operational guidance through PASS, and also participated in the CRAASH Barcelona healthcare acceleration program, organized in collaboration with Boston’s CIMIT. This journey has provided the company with the tools, knowledge and support necessary to successfully access the centralized public procurement process and roll out its technology in the country’s leading hospitals.
The exoskeletons will be used at benchmark hospitals, including Vall d’Hebron, Parc Taulí, Germans Trias i Pujol, Bellvitge, Santa Creu i Sant Pau and Hospital del Mar, all of which have Clinical Expertise Units (UEC) in neuromuscular diseases that belong to the XUEC Network.
ABLE Exoskeleton: technology to improve autonomy and quality of life
The ABLE Exoskeleton is a lightweight, ergonomic, accessible robotic device designed for gait training in individuals with bilateral impairment. It provides mechanical assistance and safety control, helping preserve mobility, improve functional outcomes and enhance patients’ autonomy.
Under the framework of PASS, the Agency for Health Quality and Assessment of Catalonia (AQuAS) has prepared a preliminary report and coordinated advisory sessions to evaluate the device’s clinical and economic impact.
This success story highlights the value of Biocat’s programs to accelerate healthcare startups and connect innovative companies with Catalonia’s healthcare system, ensuring that locally developed technological solutions reach patients and generate real value for the public healthcare system.
